Skip to content
The Nexus
DossierENTITY

DUET study

Coverage of DUET study in the Nexus archive.

Earliest in view: May 5 · 05:05 UTCMost recent: May 5 · 05:05 UTC
Co-mentioned in this coverage
Johnson & Johnsonorganization1Tremfyatopic1Simponitopic1Inflammatory Bowel Diseasetopic1
Recent coverage
  • HEALTHMay 5 · 05:05 UTCSTAT NEWS
    STAT+: Johnson & Johnson advances IBD therapy, despite trial miss

    Johnson & Johnson's therapy for inflammatory bowel disease failed to show statistically meaningful improvement, but the company plans to advance it into late-stage testing. The therapy, combining Tremfya and Simponi, performed better than individual drugs in Phase 2b clinical trials. The company will focus on a growing subgroup of patients.

DUET study · Dossier · The Nexus